Compare IDEXX Laboratories, Inc. (IDXX) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs OneSpan Inc — how do they compare? IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B), while OneSpan Inc trades at $16.57 (market cap $600.69M). The key difference: IDEXX Laboratories, Inc. is far larger — about 76.9× OneSpan Inc's market cap, and OneSpan Inc pays a 3.19% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | OSPN | |
|---|---|---|
Market Cap | $46.22B | $600.69M |
Sector | Health | Technology |
52-Week High | $766.68 | $16.78 |
52-Week Low | $526.44 | $10.15 |
Enterprise Value | $47.12B | $569.77M |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
OneSpan (OSPN) trades at $16.53, up 0.98% in the last session, with a bullish technical signal from moving averages. The stock shows strong profitability with a net income margin of 27.76% and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and the launch of DigipassONE, supporting growth in subscription revenue.
Outlook remains positive with a consensus price target of $17.00, though risks include declining net cash flow and competitive pressures. The stock offers value with a P/E of 9.21, but investors should monitor execution on guidance and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
